グルココルチコイド治療を受けている活発なポリミアルギー・リウマチア患者の疾患活動に対するトシリズマブの効果: ランダム化臨床試験
Valérie Devauchelle-Pensec1,2, Guillermo Carvajal-Alegria1,2, Emmanuelle Dernis3
1Rheumatology Department, Brest University Hospital, Brest, France.
JAMA
|September 20, 2022
まとめ
トシリズマブは多発性筋痛症の患者において,疾患の活性性を有意に改善し,プレドニゾンの使用量を減少させた. このインタールイキン-6 (IL-6) 反抗剤は,この状態に対する有望な治療法です.
科学分野:
- リウマトロジ
- 免疫学
- 臨床試験
背景:
- グルココルチコイド依存性多発性リウマチ症 (PMR) の治療法は限られている.
- インタールイキン-6 (IL- 6) 反抗剤は,活発なPMRにおける疾患の活性低下の可能性を示しています.
研究 の 目的:
- 活性な,グルココルチコイド依存性多発性筋痛症の患者におけるトシリズマブの有効性をプラセボと比較する.
主な方法:
- PMR患者101人を対象とした,二重盲検,プラセボ対照のランダム化臨床試験.
- 患者は24週間の間,標準化されたプレドニゾンの減量療法と共に,静脈内でのトシリズマブ (8 mg/ kg) またはプラセボを4週間ごとに投与された.
主要な成果:
- 主要エンドポイントは,トシリズマブ群の67. 3%とプラセボ群の31. 4%で達成された (P < . 001).
- トシリズマブはC反応性タンパク質 (CRP) 濃度とプレドニソンを必要とする患者の割合を著しく低下させた.
- トシリズマブ群の46. 9% ,プラセボ群の39. 2%で発生した.
結論:
- トシリズマブは,プラセボと比較して,活発な多発性筋痛症の管理に優れた有効性を示し,プレドニゾンの必要性を減少させた.
- これらの発見を確認し,PMR治療におけるトシリズマブの利益と害のバランスを評価するために,さらなる研究が必要である.
関連する概念動画
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
192
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
192
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
256
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
256
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
215
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
215
T Cell Types and Functions
1.3K
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
1.3K
Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids
366
Inhaled corticosteroids (ICS) are anti-inflammatory drugs used primarily in treating persistent asthma and providing long-term maintenance. They target the bronchial mucosa, the lining of the airways, to control inflammation, a critical factor in asthma progression and exacerbation.
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
366
Rheumatic Heart Disease III: Medical Management
26
Rheumatic heart disease (RHD) management can be divided into two main strategies: prevention and long-term management.Primary PreventionPrimary prevention focuses on timely diagnosis and management of group A streptococcal pharyngitis to prevent acute rheumatic fever. The most widely used antibiotic for treating this condition is intramuscular benzathine penicillin G.Acute Rheumatic Fever TreatmentThe primary treatment goal for a patient diagnosed with acute rheumatic fever is to suppress the...
26


